Cellink was founded to exploit the results of a EUREK/EUROSTAR project to develop a technology platform that would allow the biofabrication of 3D living human tissues in vitro that could be stable for weeks to months. It has grown rapidly in the past 3 years, from 24 employees to 119 as of May 2019.
Cellink's first product was a nanocellulose based bioink, together with a low-priced, entry-level bioprinter that sells for less than $5,000. The company has evolved its strategy from selling bioinks to offering a complete start-up package for beginners in bioprinting, to sale and marketing of systems consisting of several components; 3D bioprinter, stem cell bioinks, cell mixers and dosing equipment. Strategic alliances have been a key part of this process, with the company acquirers 2 parters, Dispendix and Cytena since November 2018.
Cellink is aiming for a NASDAQ listing in late 2019 or early 2020, which is reflected their expansive public relations and marketing messaging.
Holograph X
Holograph X employs high-resolution holographic stereolithography to bioprint extremely small structures.
The proprietary multiphoton laser system prints biocompatible materials with up to 150,000 points of light per second to produce a user-generated structure, such as human capillaries and ultra-fine extracellular matrices.
Click the icon to access or download the relevant document
Direct Offices:
Gothenburg, Sweden
Boston, MA; small office based in biocluster, Kendall Square
Kyoto; Small office located in Kyoto University's innovation hub.
Freiburg, Germany; Dispendix & Cytena offices.
International Distributors:
Canada: Spectra Research Corporation
USA:
The company's Q3 2018/2019 results for the period to May 31 2019 show a 135% increase in revenue to SEK 39.7m (CHF $4.0m).
REVENUE * FY2017/2019 Revenue (9 months): SEK 39.7m (US$ 4.1m) * FY2018/2019 Revenue (12 months): SEK 45.3 (US$ 4.7m)
EBITDA * FY2017/2019 Profit (9 months): SEK 1.9m (US$ 190k ) * FY2018/2019 Profit (12 months): SEK 372k (US$ 39k )
NO. EMPLOYEES: * September 2018: 24 * September 2019: 74 * May 2019: 119
Cellink is showing considerable public relations activity ahead of its planned IPO, scheduled for late 2019 ore early 2020. The articles below give an insight into the company, its founder and its strategy for growth.
Erik Gatenholm, Co-Founder & CEO, CELLINK Published on November 16, 2016
Click the Icon to download the respective document